Article

Method development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease monitoring

2026-07-13

Abstract excerpt

<h4>Background: </h4> Pancreatic cancer and ovarian cancer are very challenging to diagnose at early stages. The endoscopic retrieval of biopsy tissue from a suspected benign or malignant lesion is challenging due to the tissue’s nature. Therefore, within the Instand-NGS4P framework, we developed Measurable Residual Disease (MRD) prototypes to analyze blood plasma samples, with the aim of cost-effectively supporti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ebd38367-d2ef-53dd-a616-e2a2101124f0
DOI: 10.12688/openreseurope.23403.2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Method development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease monitoringDOI 10.12688/openreseurope.23403.2Read

Method development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease monitoringSemantic proximity Read

Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.Semantic proximity Read

Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correctionSemantic proximity Read

Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinomaSemantic proximity Read

Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity Read

Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter.Semantic proximity Read

Processing UMI Datasets at High Accuracy and Efficiency with the Sentieon ctDNA Analysis PipelineSemantic proximity Read

Validation and Clinical Utility of a Pan-Cancer Circulating Tumor DNA Assay as a First-Approach Test.Semantic proximity Read

Error-corrected deep targeted sequencing of circulating cell-free DNA from colorectal cancer patients for sensitive detection of circulating tumor DNASemantic proximity Read

Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancerSemantic proximity Read

Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.Semantic proximity Read

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.Semantic proximity Read